A B S T R A C T
Background. Estimated glomerular filtration rate (eGFR) becomes less reliable in patients with advanced chronic kidney disease (CKD). Methods. Using the Swedish CKD Registry , linked to the national inpatient, dialysis and death registers, we compared the performance of plasma-iohexol measured GFR (mGFR) and urinary clearance measures versus eGFR to predict death in adults with CKD stages 4/5. Performance was assessed using survival and prognostic models. Results. Of the 2705 patients, 1517 had mGFR performed, with the remainder providing 24-h urine clearances. Median eGFR (CKD-EPI creatinine ) was 20 mL/min/1.73 m 2 [interquartile range (IQR) [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] , mGFR 18 mL/min/1.73 m 2 (IQR 13-23) and creatinine clearance 23 mL/min (IQR 15-31). Median follow-up was 45 months (IQR 26-59), registering 968 deaths (36%). In fully adjusted Cox models, a rise in mGFR of 1 mL/min/1.73 m 2 was associated with a 5.3% fall in all-cause mortality compared with a 1.7% corresponding fall for eGFR [adjusted hazard ratio (aHR) 0.947 (95% CI, 0.930-0.964) versus aHR 0.983 (95% CI, 0.970-0.996)]. mGFR was also statistically superior in prognostic models (discrimination using logistic regression and integrated discrimination improvement). Urinary clearance measures showed a stronger aetiological relationship with death than eGFR, but were not statistically superior in the prognostic models.
Conclusions. The performance of mGFR was superior to eGFR, in both aetiological and prognostic models, in predicting mortality in adults with CKD stage 4/5, demonstrating the importance of GFR per se versus non-GFR determinants of outcome. However, the relatively modest enhancement suggests that eGFR may be sufficient to use in everyday clinical practice while mGFR adds important prognostic information for those where eGFR is believed to be biased.
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I N T R O D U C T I O N
Chronic kidney disease (CKD) is associated with adverse patient outcomes [1] . Identifying reduced glomerular filtration rate (GFR) is key for the classification of kidney disease and prognostication for patients with CKD [2] . GFR is approximated by measuring plasma clearance of an exogenous substance such as iohexol [measured GFR (mGFR)] or measuring an endogenous marker, such as creatinine. Estimated GFR (eGFR) is derived from the serum creatinine concentration, adjusted for creatinine generation on the basis of age, sex and race. Urinary creatinine excretion can be measured directly using a timed urine collection (usually 24 h) and calculating the creatinine clearance (Creat-Cl) [3] .
Creatinine-based eGFR is subject to inaccuracy; eGFR overestimates true GFR in people with low muscle mass (reduced creatinine generation), including those with advanced [4] [5] [6] , and underestimates GFR in case of high muscle mass. However, urinary creatinine excretion, which is a measure for muscle mass, is also an independent prognostic marker; low creatinine excretion is associated with increased all-cause mortality [7] . These associated observations affect the utility of creatinine-based eGFR, both as a measure of excretory kidney function (due to inaccuracy) and as a prognostic marker for increased mortality. This is because the relationship between eGFR and adverse outcomes is confounded by creatinine generation. Creatinine generation is a key non-GFR determinant of outcome. Whether accurate measure of kidney function or prognostic ability should take precedence in our choice of filtration marker is debated [8, 9] .
In Sweden, many patients with advanced CKD routinely have formal GFR measurement (mGFR or urinary urea/CreatCl) along with eGFR. To assess the contribution of GFR and non-GFR determinants to patient outcome, we compared the performance of eGFR with mGFR to predict all-cause mortality in patients registered with the Swedish Renal Registry-Chronic Kidney Disease (SRR-CKD).
M A T E R I A L S A N D M E T H O D S
Study population
SRR-CKD prospectively collects data for all patients attending 49 of 51 nephrology clinics in Sweden (2014) with incident eGFR <30 mL/min/1.73 m 2 [10] . GFR measurements (iohexol mGFR or urinary clearances of urea, creatinine or ureacreatinine) are performed routinely in most Swedish nephrology clinics, but there is no uniform protocol. This study included patients 18 years who had 'either' an iohexol mGFR 'and/or' urinary clearance [Creat-Cl, urea clearance (Urea-Cl) or urea-creatinine clearance (Urea-Creat-Cl)] 'and' a serum creatinine measurement between 1 January 2005 and 31 December 2011, on the day of a nephrology clinic visit (for contemporaneous clinical measures). Data linkage with the Swedish Inpatient Register provided comorbidity data (ICD-10 codes from 1987 onwards), to calculate Charlson scores [11] . We linked with the SRR and the Cause of Death Registry for date of renal replacement therapy (RRT) (including pre-emptive transplantation) and vital status until 30 September 2013. Duplicates were removed, then patients were excluded (criteria shown in Figure 1 ). Outlier GFR results were removed on the assumption that the result was not biologically plausible (when the absolute difference between mGFR and eGFR was >3 standard deviations (SDs) from the mean absolute population difference). Primary renal diagnosis (PRD) was reported according to the European Renal Association codes [12] .
Laboratory measurements
Iohexol is an iodinated contrast agent excreted via glomerular filtration; its elimination from plasma is used as an indirect measure of GFR. Iohexol plasma clearance is performed by injecting 2-10 mL of iohexol intravenously. After 6-24 h Creat-Cl n = 1076
Urea-Creat-Cl n = 527
Urea-Cl n = 645 
(depending on the eGFR) a blood sample is drawn and iohexol concentration is measured using high-performance liquid chromatography. mGFR is then calculated using a formula based on the individual's age, sex and distribution volume. It performs well in comparison with inulin clearance [13] . The iohexol mGFR protocols used in Swedish clinics differ only slightly and the national quality assurance program was operating during the study period [14] . A description of iohexol plasma clearance calculation is given in the Supplementary material. Swedish laboratories analysed serum creatinine using an enzymatic method or corrected Jaffe method, which are isotope dilution mass spectrometry traceable. Performance as assessed by the Swedish Clinical Chemistry Association was acceptable [15] . eGFR was calculated using the CKD-EPI creatinine formulae [16] .
Urinary urea and creatinine measurements were reported using the absolute value (mL/min) while mGFR and eGFR were reported with a correction for body surface area (BSA) of 1.73 m 2 , reflecting routine clinical care. However, for the analyses, the urinary clearance measures were corrected for BSA of 1.73 m 2 to allow a fair comparison with mGFR/eGFR.
Statistical analysis
Statistical analyses were undertaken using Statistical Package for the Social Sciences (SPSS) for Mac version 21 (IBM). Descriptive statistics are presented as mean 6 SD or median [interquartile range (IQR)]. Between-group differences were assessed according to the data distribution. Multiple imputation was performed for variables when there was <10% data missing, with 20 imputations, and pooled results used, unless otherwise specified.
The cohort was divided into tertiles according to the clearance marker [i.e. tertiles of iohexol mGFR, eGFR, Creat-Cl (all adjusted for BSA of 1.73 m
2 )], and Kaplan-Meier unadjusted survival plots were constructed comparing outcome for the clearance markers, by tertile. Cox proportional hazard survival models were constructed for all-cause mortality. Potential confounders were identified from direct acyclic graphs (DAG; dagitty.net) and the assumptions of conditional independence in the DAG were confirmed using linear regression. Covariates were included in order to assess the effects of the predictor on mortality. The DAG used to produce the models is provided in the Supplementary data, Figure S1 . The proportional hazards assumption was tested for each continuous variable by plotting Schoenfeld residuals against time, using LOESS smoothing. Log minus log plots were used for categorical variables. The proportional hazards assumption was tested by creating time-dependant covariates for each variable, assessing for interaction and were included in the model as a time-dependant covariate if the interaction was significant.
Model 1 included age and gender as covariates. Model 2 (see DAG in Supplementary data, Figure S1 ) was adjusted for: age, gender, Charlson Score, PRD, body mass index (BMI) and serum albumin. Model 3 (see DAG in Supplementary data, Figure S1 ), included Model 2 covariates plus pulse pressure, haemoglobin and commencement of RRT (time-varying covariate). Each of the predictors was added to the model 'in turn'; iohexol mGFR, eGFR, Creat-Cl, Urea-Cl and Urea-CreatCl (all adjusted for BSA of 1.73 m 2 ). The adjusted hazard ratios (aHR) presented were for a one-unit rise in the predictor variable. However, Creat-Cl is generally higher than eGFR and Urea-Cl is generally lower, introducing potential bias. Therefore, sensitivity analyses were performed; each predictor was log-transformed (not normally distributed) and then standardized for fair comparison. For these analyses, the hazard ratios are per 1 SD on a logarithmic scale. eGFR CKD-EPI creatinine was used since it is recommended by KDIGO and performed well in comparison with iohexol mGFR in a crosssectional analysis of the SRR-CKD [2, 4] . Sensitivity analyses were also performed comparing the performance of the urinary clearance markers without correction for BSA.
Several methods were used to estimate the predictive performance of a model. The diagnostic performance was studied through discrimination, separating those diagnosed with the event from those not experiencing it. In this context, good discrimination means that low GFR always produces higher predicted risk than high GFR. In our study, model discrimination was assessed using C-statistics derived by two methods. Multivariate logistic regression models for 2-year, all-cause mortality were built using each predictor in turn with the covariates from the Cox model 3 (using data from the 20th imputation). The C-statistics were calculated by constructing receiver operator characteristic (ROC) curves using the predicted probability from the logistic regression model. Differences between the area under the curve (AUC) of ROC curves was assessed using Hanley and McNeil's method [17] . In addition, Harrell's C was calculated for each clearance measure using the output from the adjusted Cox survival model, utilizing the total followup time available (using Model 3 and data from 20th imputation) [18] . These models were built in order to compare the performance of the different measures of renal function, and not for clinical use as a predictor of prognosis.
Calibration assesses the agreement between the observed and the predicted risk by the model. Calibration was assessed using the Hosmer-Lemeshow test; a non-significant P-value suggests model calibration (i.e. no significant difference in proportion of participants predicted versus observed to die). Integrated discrimination improvement (IDI) compared the performance of mGFR or urinary clearance measures versus eGFR (as reference) to predict all-cause mortality. The same multivariate model was used as for discrimination. IDI measures the proportion correctly reclassified to a higher or lower risk with the addition of the new biomarker. It is superior to net reclassification index as it incorporates direction and magnitude of risk reclassification, and does not rely on a selected threshold [19] .
R E S U L T S
The cohort included 2705 patients, 1517 with an iohexol mGFR and eGFR performed contemporaneously and 1188 with a urinary clearance and eGFR measured contemporaneously; see the flowchart of population and exclusions ( Figure 1 ). Background data are shown in Table 1 , except data regarding race (illegal ii172 S. Methven et al.
to record in Sweden). Patients were followed for a median of 45 months (IQR 26-59). Scatterplots demonstrating the relationship between the measures of GFR are shown in Supplementary data, Figure S2 .
OUTCOMES
There were 968 deaths during follow-up (35.8% of the total cohort). For those who died during follow-up, median time to death from baseline was 23 months (IQR 11-39). RRT was commenced in 1087 patients (40.2%). There were 621 deaths (23.0%) without starting RRT and 347 patients (12.8%) died after starting RRT. Subsequent mortality analyses include all deaths (with or without RRT initiation). See Figure 1 for details of the mGFR and urinary clearance subgroups.
AETIOLOGICAL MODELS
mGFR versus eGFR to predict mortality. Kaplan-Meier plots of unadjusted survival, comparing tertiles of clearance marker, are shown in Figure 2 . Cox regression analyses comparing iohexol mGFR and eGFR as predictors of all-cause mortality are shown in Table 2 and Figure 3 (unadjusted model) and Supplementary data, Figure S3 (adjusted model). Given the inverse relationship between GFR and survival, a lower aHR is suggestive of a stronger relationship between the measure of GFR and all-cause mortality. In the fully Urinary clearance versus eGFR to predict mortality. Cox regression analyses comparing urinary clearance measures and eGFR as predictors of all-cause mortality were performed. Multiple measures of urinary clearance were available in different subgroups (see Figure 1) . Multiple comparisons were only made when all measures were available contemporaneously in a subgroup.
Creat-Cl was measured in 1076 participants and the comparison with eGFR is shown in Table 3 For each measure of kidney function (the predictor), the unadjusted hazard ratio is shown, followed by three models with covariates, as described above (95% CI in brackets). The predictor variables were not normally distributed, therefore they were converted to a logarithmic scale. Then, in order to facilitate direct comparison the predictor variables were standardized (mean of 0 and standard deviation of 1). In summary, the hazard ratios are described for the crude measure of the predictor and then per 1-SD rise on a logarithmic scale. Figure S3 (adjusted model). Urea-Creat-Cl was measured in 527 participants and the comparisons with Creat-Cl, Urea-Cl and eGFR are shown in Table 4 , Figures 2 and 3 (unadjusted model) and Supplementary data, Figure S3 (adjusted model).
Urinary Creat-Cl versus eGFR.
In the fully adjusted Cox model (Model 3, Table 3 Table 4 ). In the sensitivity analyses, a markedly altered relationship is observed, with a 1-SD rise in Urea-Cl (logarithmic scale) associated with 26.3% lower mortality versus 3.1% [aHR 0.737 (95% CI, 0.631-0.860) and aHR 0.969 (95% CI, 0.833-1.128), respectively], in the fully adjusted model.
Urinary Urea-Creat-Cl.
For Urea-Creat-Cl versus eGFR, mortality was 3.0% versus 0.9% lower [aHR 0.970 (95% CI, For each measure of kidney function (the predictor), the unadjusted hazard ratio is shown, followed by three models with covariates, as described above. The predictor variables were not normally distributed, therefore they were converted to a logarithmic scale. Then, in order to facilitate direct comparison the predictor variables were standardized (mean of 0 and standard deviation of 1). In summary, the hazard ratios are described for the crude measure of the predictor and then per 1-SD rise on a logarithmic scale. For each measure of kidney function (the predictor), the unadjusted hazard ratio is shown, followed by three models with covariates, as described above (95% CI in brackets). The predictor variables were not normally distributed, therefore they were converted to a logarithmic scale. Then, in order to facilitate direct comparison the predictor variables were standardized (mean of 0 and standard deviation of 1). In summary, the hazard ratios are described for the crude measure of the predictor (corrected for BSA) and then per 1-SD rise on a logarithmic scale. Table 4 ). In the sensitivity analyses, an altered relationship is again observed, with a 1-SD rise in Urea-Creat-Cl (on a logarithmic scale) associated with 24.3% lower mortality versus 3.1% [aHR 0.757 (95% CI, 0.648-0.884) and aHR 0.969 (95% CI, 0.833-1.128), respectively], again when the model was fully adjusted for covariates. Therefore, within the subgroup with multiple urine clearance measures, the Urea-Cl had the strongest relationship with allcause mortality. Sensitivity analyses were also performed for the urinary clearance markers without adjustment for BSA (shown in Supplementary data, Tables S1 and S2) and the relative performance of the clearance markers was unchanged.
PROGNOSTIC MODELS
Discrimination and calibration. Model discrimination for mGFR, Creat-Cl and Urea-Creat-Cl, compared with eGFR are shown in Figure 4 (and Supplementary data, Table S3 ). The C-statistic (from the 2-year logistic regression model) was significantly higher for mGFR than eGFR, demonstrating superior discrimination, using Hanley and McNeil's method of comparing the AUC of ROC curves [17] . The parameter estimates for variables in the logistic regression models are shown in Supplementary data, Table S4. In the urinary clearance groups, the differences were not significant. Using Harrell's C, the relative discriminative performance of the clearance measures was the same as the logistic regression method, except for mGFR and eGFR where no clear difference was seen between the two measures. All the models were well calibrated using Hosmer-Lemeshow goodness of fit test (no significant differences between the expected and observed proportion who died) (Supplementary data, Table S3 ).
Integrated discrimination improvement. IDI was used to assess improvement in the prognostic model with mGFR or urinary clearance measures in place of eGFR. The results are shown in Supplementary data, Table S5 . Replacing eGFR with mGFR resulted in a improvement in the IDI (overall IDI 0.023). However, replacement of eGFR with Creat-Cl, Urea-Cl or Urea-Creat-Cl did not result in a significant change in the IDI.
D I S C U S S I O N
We have shown that mGFR (iohexol plasma clearance) is a superior predictor of all-cause mortality than eGFR in a Swedish registry population of patients with CKD. However, the demonstration of a stronger relationship does not necessarily mean that the predictor has a superior influence on prognosis. Therefore both aetiological models (to demonstrate the strength of the relationship) and prognostic models (to compare the contribution of the respective markers to prognostication) are needed, as performed here. In our models we show that the mGFR is consistently superior across the aetiological Cox models (adjusted and unadjusted), demonstrating the importance of GFR itself as a predictor of adverse outcome over the additional non-GFR determinants of outcome associated with creatininederived eGFR. Prognostic models were built to allow comparison of the performance of the markers, and have not been validated for clinical use to estimate prognosis. mGFR was also generally superior to eGFR in the prognostic models (discrimination using 2-year logistic regression model, calibration and IDI, but discriminative performance of mGFR and eGFR was similar using Harrell's C).
However, the relative performance of mGFR in the prognostic models was weaker than the aetiological models. Creatininebased eGFR using the CKD-EPI formulae performed well in the prognostic model, and while mGFR was superior, the difference was modest (at best) and may not be clinically relevant.
In a separate subgroup, urinary clearance measures were performed. There were significant differences in the baseline characteristics between the iohexol mGFR group and the urinary clearance group, therefore direct comparisons between mGFR and urinary clearance cannot be made. However, comparisons can be made between different urinary clearance measures performed in the same patients. Supplementary data, Figure S2 demonstrates the relationship between Creat-Cl, Urea-Cl and combined Urea-Creat-Cl versus eGFR, respectively, in the cohort. Creat-Cl is generally higher than eGFR for a given patient due to a relative increase in tubular secretion of creatinine in advanced CKD (median Creat-Cl 23 mL/min), Urea-Cl is lower due to tubular reabsorption (median Urea-Cl 14 mL/min), and the combined Urea-Creat-Cl is closest to eGFR in the cohort , respectively). Urinary clearance measures showed less consistent performance than mGFR across the aetiological and prognostic models. Given the systematic differences in measurement of the filtration markers observed above (e.g. Creat-Cl being consistently higher than Urea-Cl at a given level), the sensitivity analyses aided interpretation (using log transformation and standardization to remove these differences). Each urinary filtration marker showed a strong independent relationship with all-cause mortality in the aetiological models, similar in magnitude to each other and stronger than eGFR. However, while they showed good discrimination, this was not significantly superior to eGFR. The models were well calibrated, but again, using the IDI, were not superior to eGFR. The strongest performer among the urinary markers was Urea-Cl.
Iohexol plasma clearance performs well compared with inulin clearance, the historic gold standard GFR measure [13] . It is considered to be more accurate than eGFR as it is closer to 'true GFR'. Worsening kidney disease is associated strongly with increased all-cause mortality [1, 20] . However, eGFR equations were developed to estimate GFR, not for prognostication (though GFR itself is a strong predictor of prognosis). However, it does not necessarily follow that iohexol mGFR is a superior predictor of all-cause mortality, as mGFR does not take account of non-GFR determinants of outcome such as protein-energy wasting, low muscle mass and reduced creatinine generation. In a post hoc analysis of the MDRD study, Tangri et al. demonstrated that, after adjusting for GFR in their multivariate model, a higher creatinine remained independently associated with lower mortality, demonstrating the role of the non-GFR determinants of creatinine [21] . Conversely, low spot urine creatinine concentration is independently associated with mortality [22] . Other works demonstrated an association between creatinine and nontraditional cardiovascular risk factors, independent of GFR [23] . However, in this study we have demonstrated the superior performance of mGFR over eGFR in the aetiological Cox models. A previous SRR-CKD study showed that the CKD-EPI creatinine formulae overestimate GFR in advanced kidney disease [4] . Our findings suggest that the superior accuracy of mGFR (and the independent relationship between GFR and all-cause mortality) outweighs the aetiological effects of the non-GFR determinants of outcome as measured by creatinine.
The lack of superiority shown for formal urinary measures over eGFR (especially Creat-Cl and Urea-Creat-Cl) may be because these measures reflect the same creatinine based non-GFR determinants of outcome as eGFR, or simply due to inaccuracies in the urine collections. Urea-Cl performed well to predict all-cause mortality. While it is inferior for measuring GFR alone (40-50% of filtered urea may be reabsorbed in the tubules), higher urea generation may reflect high protein content in the diet [3] . Therefore, this may be a marker of good patient outcome. The lack of a significant difference in discrimination and IDI for urinary measures over eGFR may simply reflect lack of statistical power [though discrimination models were consistent between the Creat-Cl group (n ¼ 1076) and the Urea-Creat-Cl group (n ¼ 527)].
Calculating eGFR from a blood sample is undoubtedly the most convenient GFR assessment for patient, clinician and laboratory, not to mention cost effectiveness, and must be advocated for widespread use to identify those with CKD [24] . Since eGFR reporting was introduced, timed urine collection use has fallen dramatically in many countries, although is still advocated by some for patients with advanced CKD [25] . However, clinical practice differs between countries and we have exploited the ongoing practice of formal measures in Sweden for this study. In advanced CKD, where accurate measures of GFR will aid decision-making regarding timing of RRT, vascular access formation or drug dosing, and the eGFR formulae are least accurate, clear benefits of a formal measure of GFR are seen. We have demonstrated the strong aetiological relationship with mortality, which may aid prognostication in patients with advanced CKD.
The strengths of this study lie in the inclusive, representative nature of the cohort, the large numbers undergoing mGFR testing and the complete follow-up of patients using linked national Swedish Registries. However, there are also limitations. As the study utilizes routinely collected data, participants had the formal measure of GFR of their nephrologist's choice, which could introduce confounding by indication. Only a subset had multiple contemporaneous measures, limiting direct comparisons. While data regarding date of death were complete, data regarding the cause of death were not, which limited the analyses to all-cause mortality only. Ethnicity data were not recorded due to Swedish regulations. However, the proportion of people from minority ethnic groups is low in Sweden and the findings will reflect the majority white population. These findings, therefore, may not translate to other ethnic groups. Data regarding smoking status and albuminuria were incomplete so these variables could not be included in the models. We did not have additional endogenous measures of kidney function such as cystatin C or beta trace protein to compare with the exogenous measures. Lastly, iohexol mGFR is itself only an estimate of true GFR (which cannot be directly measured) and we used only a single time-point, so we were unable to investigate the influence of GFR slope on outcomes, as has been done elsewhere [26] .
These findings should be confirmed in a prospective cohort to exclude residual confounding or selection bias. Obtaining urinary measures, endogenous measures of eGFR and mGFR contemporaneously would allow direct comparisons.
In conclusion, in aetiological and prognostic models, mGFR was superior to eGFR in predicting mortality in adults with CKD stage 4/5 attending Swedish nephrology clinics. This demonstrates the strong aetiological role of GFR to predict adverse outcome versus the additional non-GFR determinants of outcome associated with creatinine-based eGFR. The relatively modest predictive enhancement suggests that eGFR may be sufficient to use in most scenarios in everyday clinical practice, while mGFR adds prognostic information when eGFR is believed or suspected to be biased.
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